No substitutes available
Enhertu 100mg Injection contains Trastuzumab deruxtecan, an advanced targeted anticancer therapy used to treat HER2-positive and HER2-low cancers. It is most commonly prescribed for metastatic or unresectable breast cancer, gastric (stomach) cancer, and selected cases of non-small cell lung cancer (NSCLC) in adults. Enhertu is an antibody–drug conjugate (ADC), meaning it combines targeted therapy with chemotherapy in a single molecule, allowing direct delivery of cancer-killing medication to tumor cells while limiting damage to healthy tissues.
Enhertu is administered as an intravenous infusion, typically once every 3 weeks, under strict medical supervision. Due to its potency and risk of serious side effects—especially lung and heart complications—patients require close monitoring throughout treatment. This medicine is not recommended for individuals below 18 years of age.
Enhertu 100mg Injection is used for the treatment of:
Enhertu works through a dual-action targeted mechanism. The trastuzumab component binds specifically to HER2 receptors on cancer cells, allowing precise targeting. Once attached, the drug releases DXd, a potent cytotoxic agent, directly inside the cancer cell. This leads to DNA damage and cell death. This targeted delivery enhances cancer-killing effectiveness while reducing exposure to surrounding healthy tissues.
Side Effects of Enhertu 100mg Injection
Like all medications, Enhertu 100mg Injection may cause side effects. However, not everyone will experience them.
Serious Side Effects (Seek immediate medical attention):
Common Side Effects (Usually mild and temporary):
Enhertu 100mg Injection is administered via intravenous infusion once every 3 weeks by a trained healthcare professional. The exact dose and duration depend on cancer type, disease progression, and patient tolerance. Pre-medications may be given to reduce nausea and infusion reactions. Self-administration is strictly not permitted.
Breastfeeding is not recommended during treatment, as the medicine may pass into breast milk and harm the baby.
Alcohol does not have a known direct interaction but may worsen side effects such as nausea or headache. Consult your doctor before consuming alcohol.
Patients with a history of lung disease are at higher risk of serious lung complications. Any new or worsening breathing symptoms should be reported immediately.
Enhertu usually does not impair driving, but dizziness or fatigue may occur. Avoid driving if you feel unwell.
Enhertu can cause harm to the unborn baby. Women should use effective contraception during treatment and for at least 7 months after the last dose. Men should continue contraception for 4 months after treatment.
Treatment continues as long as the patient benefits and tolerates therapy without unacceptable side effects. Duration varies based on response and disease progression.
Enhertu delivers a higher-potency cytotoxic drug and has a “bystander effect,” allowing it to kill nearby cancer cells even those with lower HER2 expression making it effective in HER2-low cancers.
Yes, interstitial lung disease is a known risk. Early detection is critical, so patients must report cough, shortness of breath, or fever immediately.
Yes. Enhertu may impact fertility. Patients planning future pregnancies should discuss fertility preservation options before starting treatment.
Most patients can continue routine activities, but fatigue and other side effects may require adjustments. Always follow your doctor’s personalized guidance.
| Active ingredient | Trastuzumab deruxtecan |
| Pharmacologic class | HER2 Inhibitor (Antibody-Drug Conjugate) |
| Medication category | ANTI NEOPLASTICS |
| Dosage forms | Injection |
The information on the Phoenix Pharmex website is shared for educational purposes only and is not a substitute for professional medical advice or treatment. Always consult a doctor for any health-related questions. Please avoid self diagnosis or delaying medical care based on this content. Our mission is to support informed decisions not replace professional medical guidance.
Azadine 100mg Injection contains Azacitidine which belongs to the group of medicines called Anticancer agents. It is used in adults to treat all sub-types of myelodysplastic syndromes (MDS; group of cancers associated with blood and bone marrow) and certain types of blood cancers known as Chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).
Azadine 100mg Injection is typically used in adults who cannot undergo stem cell transplantation. It may be also used to treat other conditions, as determined by the doctor.
Azadine Injection is given as an injection under the medical supervision of a doctor. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised.
You must inform your doctor before taking any vaccination while on treatment with this medicine. Regular blood tests are required to check your blood cells along with the heart, liver, and kidney.
Before taking it, tell your doctor if you have liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your doctor know all medications you are using.
Azadine 100mg Injection is an anticancer medication. It works by blocking the actions of certain enzymes (DNA/RNA methyltransferase) within the cancer cells that is required for the cells to grow and multiply. It also reduces the production of new genetic material (RNA and DNA) within the cells. As a result, it prevents abnormal cell division within the body, slows down the growth of cancer cells and helps the bone marrow to produce normal blood cells.
It is used to treat:
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Ques 1: What is the use of AZADINE 100MG INJECTION?
Ans :AZADINE 100MG INJECTION is used in adults to treat all sub-types of myelodysplastic syndromes (MDS; group of cancers associated with blood and bone marrow) and certain types of blood cancers known as Chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).
Ques 2: How does AZADINE 100MG INJECTION works?
Ans :AZADINE 100MG INJECTION is an anticancer medication. It works by blocking the actions of certain enzymes (DNA/RNA methyltransferase) within the cancer cells that is required for the cells to grow and multiply. It also reduces the production of new genetic material (RNA and DNA) within the cells. As a result, it prevents abnormal cell division within the body, slows down the growth of cancer cells and helps the bone marrow to produce normal blood cells.
Ques 3: Can I take AZADINE 100MG INJECTION during breastfeeding?
Ans :No. AZADINE 100MG INJECTION is not recommended for use in breast-feeding women. Therefore, inform your doctor before receiving it.
Ques 4: Can AZADINE 100MG INJECTION increase the risk of infections?
Ans :AZADINE 100MG INJECTION may cause a drop in the number of white blood cells in the body and may weaken your immune system. As a result, you may be at a greater risk of getting infected while receiving AZADINE 100MG INJECTION. To avoid this, your doctor will regular monitor your blood counts as a precaution. However, inform your doctor if you experience any signs of infection such as fever.
Ques 5: Can the use of AZADINE 100MG INJECTION make me feel tired?
Ans :Yes. AZADINE 100MG INJECTION may make you feel tired easily. This is because, it reduces the levels of red blood cells in your blood and may make you anemic. Consult your doctor if you experience tiredness after receiving AZADINE 100MG INJECTION. Tiredness can also occur if you have any pre-existing disease conditions such as liver or kidney impairment while receiving this medicine.
Ques 6: Can I drive a car after receiving AZADINE 100MG INJECTION?
Ans :AZADINE 100MG INJECTION may make you feel tired or weak. Therefore, do not drive or operate any heavy tools or machines if your ability is affected by AZADINE 100MG INJECTION.
Ques 7: How AZADINE 100MG INJECTION is administered?
Ans :AZADINE 100MG INJECTION will be given to you only by a doctor or a nurse beneath the skin (subcutaneously) of thighs, arms or abdomen.
Ques 8: How to control nausea caused due to AZADINE 100MG INJECTION?
Ans :Generally, anticancer medicines are associated with uncontrollable nausea and vomiting. To avoid this, your doctor would prescribe a suitable medicine to control them along with AZADINE 100MG INJECTION. If not, consult your doctor for a suitable anti-emetic medicine. Do not self-treat nausea.
Enhertu 100mg Injection contains Trastuzumab deruxtecan, an advanced targeted anticancer therapy used to treat HER2-positive and HER2-low cancers. It is most commonly prescribed for metastatic or unresectable breast cancer, gastric (stomach) cancer, and selected cases of non-small cell lung cancer (NSCLC) in adults. Enhertu is an antibody–drug conjugate (ADC), meaning it combines targeted therapy with chemotherapy in a single molecule, allowing direct delivery of cancer-killing medication to tumor cells while limiting damage to healthy tissues.
Enhertu is administered as an intravenous infusion, typically once every 3 weeks, under strict medical supervision. Due to its potency and risk of serious side effects—especially lung and heart complications—patients require close monitoring throughout treatment. This medicine is not recommended for individuals below 18 years of age.
Enhertu 100mg Injection is used for the treatment of:
Enhertu works through a dual-action targeted mechanism. The trastuzumab component binds specifically to HER2 receptors on cancer cells, allowing precise targeting. Once attached, the drug releases DXd, a potent cytotoxic agent, directly inside the cancer cell. This leads to DNA damage and cell death. This targeted delivery enhances cancer-killing effectiveness while reducing exposure to surrounding healthy tissues.
Side Effects of Enhertu 100mg Injection
Like all medications, Enhertu 100mg Injection may cause side effects. However, not everyone will experience them.
Serious Side Effects (Seek immediate medical attention):
Common Side Effects (Usually mild and temporary):
Enhertu 100mg Injection is administered via intravenous infusion once every 3 weeks by a trained healthcare professional. The exact dose and duration depend on cancer type, disease progression, and patient tolerance. Pre-medications may be given to reduce nausea and infusion reactions. Self-administration is strictly not permitted.
Breastfeeding is not recommended during treatment, as the medicine may pass into breast milk and harm the baby.
Alcohol does not have a known direct interaction but may worsen side effects such as nausea or headache. Consult your doctor before consuming alcohol.
Patients with a history of lung disease are at higher risk of serious lung complications. Any new or worsening breathing symptoms should be reported immediately.
Enhertu usually does not impair driving, but dizziness or fatigue may occur. Avoid driving if you feel unwell.
Enhertu can cause harm to the unborn baby. Women should use effective contraception during treatment and for at least 7 months after the last dose. Men should continue contraception for 4 months after treatment.
Treatment continues as long as the patient benefits and tolerates therapy without unacceptable side effects. Duration varies based on response and disease progression.
Enhertu delivers a higher-potency cytotoxic drug and has a “bystander effect,” allowing it to kill nearby cancer cells even those with lower HER2 expression making it effective in HER2-low cancers.
Yes, interstitial lung disease is a known risk. Early detection is critical, so patients must report cough, shortness of breath, or fever immediately.
Yes. Enhertu may impact fertility. Patients planning future pregnancies should discuss fertility preservation options before starting treatment.
Most patients can continue routine activities, but fatigue and other side effects may require adjustments. Always follow your doctor’s personalized guidance.
| Active ingredient | Trastuzumab deruxtecan |
| Pharmacologic class | HER2 Inhibitor (Antibody-Drug Conjugate) |
| Medication category | ANTI NEOPLASTICS |
| Dosage forms | Injection |
The information on the Phoenix Pharmex website is shared for educational purposes only and is not a substitute for professional medical advice or treatment. Always consult a doctor for any health-related questions. Please avoid self diagnosis or delaying medical care based on this content. Our mission is to support informed decisions not replace professional medical guidance.
Life-Saving Medicines Expert
Affordable Patient-Centered Care
Authentic, Top-Quality Medicines
Careful & Timely Medicine Deliveries
Login with Facebook
Login with Google
